These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17085306)

  • 21. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.
    Martínez C; Solano C; Ferrá C; Sampol A; Valcárcel D; Pérez-Simón JA;
    Biol Blood Marrow Transplant; 2009 May; 15(5):639-42. PubMed ID: 19361757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
    Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
    Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis.
    Schmitt T; Luft T; Hegenbart U; Tran TH; Ho AD; Dreger P
    Bone Marrow Transplant; 2011 Apr; 46(4):580-5. PubMed ID: 20562925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inolimomab (OPi).
    Winkler M
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1464-7. PubMed ID: 12431019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How can we help patients with refractory chronic graft versus host disease- single centre experience.
    Rzepecki P; Barzal J; Sarosiek T; Oborska S; Szczylik C
    Neoplasma; 2007; 54(5):431-6. PubMed ID: 17688373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease.
    Schmidt-Hieber M; Fietz T; Knauf W; Uharek L; Hopfenmüller W; Thiel E; Blau IW
    Br J Haematol; 2005 Aug; 130(4):568-74. PubMed ID: 16098072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
    Ayuk F; Perez-Simon JA; Shimoni A; Sureda A; Zabelina T; Schwerdtfeger R; Martino R; Sayer HG; Alegre A; Lahuerta JJ; Atanackovic D; Wolschke C; Nagler A; Zander AR; San Miguel JF; Kröger N
    Haematologica; 2008 Sep; 93(9):1343-50. PubMed ID: 18641030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease.
    Iyer RV; Hahn T; Roy HN; Battiwalla M; Cooper M; Anderson B; Paplham P; Brown K; Bambach B; Segal BH; McCarthy PL
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):587-92. PubMed ID: 16041308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease.
    Perales MA; Ishill N; Lomazow WA; Weinstock DM; Papadopoulos EB; Dastigir H; Chiu M; Boulad F; Castro-Malaspina HR; Heller G; Jakubowski AA; O'Reilly RJ; Small TN; Young JW; Kernan NA
    Bone Marrow Transplant; 2007 Sep; 40(5):481-6. PubMed ID: 17618322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease.
    Fang B; Song Y; Liao L; Zhang Y; Zhao RC
    Transplant Proc; 2007 Dec; 39(10):3358-62. PubMed ID: 18089385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of corticosteroid refractory acute GVHD treated with an Inolimomab-based algorithm: a single center experience.
    Girerd S; Renaud M; Guilhot J; Giraud C; Larchee R; Jollet I; Guilhot F
    Bone Marrow Transplant; 2013 Sep; 48(9):1243-8. PubMed ID: 23503532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemorrhagic cystitis: a retrospective single-center survey.
    Hassan Z; Remberger M; Svenberg P; Elbander M; Omazic B; Mattsson J; Conrad R; Svahn BM; Ahlgren A; Sairafi D; Aschan J; Le Blanc K; Barkholt L; Ringdén O
    Clin Transplant; 2007; 21(5):659-67. PubMed ID: 17845642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
    Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
    Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of steroid-resistant acute graft-vs-host disease after allogeneic marrow transplantation with anti-interleukin-2 receptor antibody (BT563).
    Hertenstein B; Stefanic M; Sandherr M; Bunjes D; Mertens T; Arnold R
    Transplant Proc; 1994 Dec; 26(6):3114-6. PubMed ID: 7998086
    [No Abstract]   [Full Text] [Related]  

  • 39. Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease.
    Melson J; Jakate S; Fung H; Arai S; Keshavarzian A
    Am J Hematol; 2007 Oct; 82(10):881-6. PubMed ID: 17570511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD).
    Castilla C; Pérez-Simón JA; Sanchez-Guijo FM; Díez-Campelo M; Ocio E; Pérez-Persona E; López-Villar O; Vazquez L; Caballero D; San Miguel JF
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):936-41. PubMed ID: 16920559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.